China, Merck and Gardasil

Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook
Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.
Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country. | The recent decline of Merck & Co.
Merck shares tumble as company pauses Gardasil shipments to China
Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.
Merck sinks 10% as company halts Gardasil shipments to China, weighing on outlook
Merck &Company Inc (NYSE:MRK) shares tumbled more than 10% Tuesday after reporting mixed fourth-quarter results, with earnings falling short of expectations, revenue surpassing estimates and full-year guidance coming in below analyst projections.
Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.
Merck stops Gardasil shipments to China, hitting 2025 outlook; shares tumble
Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong fourth-quarter profit on sales of cancer drug Keytruda.
Merck’s Gardasil Halt Shows Blockbuster Shots’ Dilemma in China
Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US pharmaceutical giant made the call earlier this week to halt shipments.
Merck Stock Loses 9% on Vaccine Shipment Halt to China
Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The pharmaceutical
Merck Stock Tumbles on Weak Guidance, Bad News in China for Gardasil Sales
Merck’s problems in China seem to be getting worse, raising questions about the company’s growth. Trouble with sales of Merck’s Gardasil HPV vaccine in China, disclosed six months ago, has unsettled investors,
Merck & Co., Inc. (NYSE:MRK) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...
Merck: Don't Fight The Tape, How Low Can It Go?
Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines.
Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...
Jim Cramer on Merck & Co., Inc. (MRK): ‘I Bet The Numbers Will Be Good, But There Are Other Issues’
We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...
Merck beats estimates on fourth-quarter on earnings—but stock slides pre-market on tepid 2025 guidance
Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...
Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
Merck Is Suffering From a Classic Pharma Problem
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Is Merck & Co. (MRK) the Best Dividend Stock to Buy and Hold?
We recently published a list of 15 Best Dividend Stocks To Buy and Hold. In this article, we are going to take a look at ...